Monitoring patient safety is of the utmost importance when running a clinical trial, but recording and reporting side effects can be labour-intensive and costly.
There’s no doubt that CAR-T therapies have transformed the treatment of many blood cancers, but a risk of secondary malignancies has cast a pall over the class.
The death of a young boy with Duchenne muscular dystrophy (DMD) who was treated with Pfizer’s experimental gene therapy in a phase 2 trial has prompted the company to paus
There is no evidence of an increased risk of suicidal or self-injurious thoughts and actions with GLP-1 agonists used to treat diabetes and obesity, according to the EU me
In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Luca Quagliata, Vice President and Global Head of Medical and Scientific Affairs at Thermo Fisher Scientific, a company